Burning rock's liquid biopsy assay achieved strong performance in the fda-led seqc2 study, with results published on nature biotechnology

Guangzhou, china, april 13, 2021 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced that its liquid biopsy assay has achieved strong performance in the fda-led sequencing quality control phase 2 (seqc2) study, the results of which have been published on nature biotechnology.
BNR Ratings Summary
BNR Quant Ranking